Gossamer Bio Inc
NASDAQ:GOSS
Gossamer Bio Inc
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 185 full-time employees. The company went IPO on 2019-02-08. The firm is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The firm's product candidates include Seralutinib (GB002), GB004, GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB004 is a gut-targeted, oral small molecule being developed for the treatment of inflammatory bowel disease (IBD). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS).
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 185 full-time employees. The company went IPO on 2019-02-08. The firm is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The firm's product candidates include Seralutinib (GB002), GB004, GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB004 is a gut-targeted, oral small molecule being developed for the treatment of inflammatory bowel disease (IBD). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS).
Enrollment Milestone: Gossamer completed patient screening for the Phase III PROSERA study of seralutinib in pulmonary arterial hypertension (PAH), with full enrollment expected by mid-June.
Data Timeline: Top-line results from PROSERA are now anticipated in February 2026, as the company chose to honor demand from patients and physicians and enroll all eligible screened patients.
Patient Population: The enrolled PROSERA population is sicker and more functionally impaired than prior studies, which the company believes increases the trial's chance of success.
Second Phase III Launch: The CIRANATA Phase III trial for seralutinib in PH-ILD (pulmonary hypertension with interstitial lung disease) is on track to start site activations in Q4 2025.
Financial Position: Gossamer ended Q1 2025 with $257.9 million in cash and equivalents, and expects this to fund operations through the first half of 2027.
Seralutinib’s Positioning: Management sees seralutinib as a potential backbone therapy for PAH, aiming for commercial differentiation via efficacy, safety, and a unique mechanism.
Market Opportunity: Both PAH and PH-ILD represent large, underserved markets with significant unmet need, and management sees multi-billion dollar potential for seralutinib.
